LM-168 combined with other treatments for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have advanced cancer that has come back or spread after standard treatments (or no standard treatment exists).
- You must be in relatively good health (able to do daily activities with little to no help) and expected to live at least 3 months.
- You cannot have had certain cancer treatments within the past few weeks to a month (like chemotherapy, immunotherapy, or targeted pills) before starting the study drug.
- You must not have active brain metastases, uncontrolled fluid buildup in the body, or serious autoimmune disease.
- You must not have had a severe allergic reaction to a similar antibody drug before, and if you have a history of organ transplant or HIV, you are not eligible.
- If you are interested in the combination with docetaxel, you cannot have had taxane chemotherapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
This trial tests a new drug (LM-108) combined with an existing immunotherapy (toripalimab) for people with advanced cancers that have a specific genetic feature (MSI-H or dMMR). The goal is to see if this combination can help when previous immunotherapy hasn't worked.
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called LM-24C5 for people with advanced solid tumors that have stopped responding to standard treatments or who can't tolerate them. It aims to see if the drug is safe and effective.
This study tests an investigational drug called LM-364, either by itself or combined with other cancer therapies, in people with advanced solid tumors. The goal is to see if the drug is safe and effective, and it may offer a new treatment option.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.